YARAL Pharma
Claim This Podcastby yaralpharma
Podcast Overview
<div class="elementToProof">Welcome to Meet YARAL, a podcast designed to bridge the gap between pharmaceutical companies and the pharmacy profession through candid conversations with pharmacists, healthcare leaders, and YARAL’s executive team.</div> <div class="elementToProof">Each episode highlights the vital role pharmacists play in patient care, unpacks challenges on the front lines, and explores how thoughtful collaboration can lead to better outcomes. Along the way, we share how YARAL’s “Doing Things Differently” approach is helping redefine relationships between industry and practice—from product innovation to patient impact.</div> <div class="elementToProof">YARAL Pharma, launched in 2022, is the U.S. generics subsidiary of IBSA, a longstanding multinational pharmaceutical company headquartered in Lugano, Switzerland. The company is committed to delivering high-quality products across various therapeutic areas, ensuring continuity of supply, and providing affordable authorized and complex generic medicines.</div> <div class="elementToProof">Subscribe to Meet YARAL and be part of the conversation that’s strengthening collaboration between pharmacy and the pharmaceutical industry.</div>
Language
🇺🇲
Publishing Since
2/29/2024
1 verified phone number on file for YARAL Pharma
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
March 23, 2026
Reliable Supply, Real Impact: How Consistent, On-Time Delivery Supports Pharmacy Operations | Yaral Pharma
In this industry-focused, conversational interview, Pharmacy Podcast Network Host Todd Eury speaks with Stephen Beckman, CEO of YARAL Pharma. The discussion explores YARAL Pharma’s commitment to continuity of supply, how consistent on-time delivery supports pharmacy operations, and the company’s philosophy of “Doing Things Differently” — redefining what it means to be a trusted generics partner.
October 9, 2025
Hypothyroidism in Long-Term Care: The Pharmacist's Role | YARAL Pharma
This podcast is sponsored by YARAL Pharma. In this episode, we are focusing on the management of hypothyroidism -- a treatable, but not curable condition – and will explore unique challenges for patients with hypothyroidism in long-term care – from tolerability and formulation considerations to consistent dosing and patient needs. Dr. Tamara Ruggles is not affiliated with YARAL Pharma. All views and opinions regarding hypothyroidism are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network. IMPORTANT SAFETY INFORMATION for levothyroxine sodium capsules INDICATION AND USAGE Levothyroxine sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer Limitations of Use: Levothyroxine sodium capsules are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine sodium capsules may induce hyperthyroidism. Levothyroxine sodium capsules are not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium capsules, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. Contraindications Uncorrected adrenal insufficiency Warnings and Precautions Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate Levothyroxine sodium capsules at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium capsules treatment Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose Adverse Reactions Common adverse reactions with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional ability, insomnia Musculoskeletal: tremors, muscle weakness Cardiovascular: palpitations, tachycardia, arrythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal (GI): diarrhea, vomiting, abdominal
July 30, 2025
Targeted Acute Pain Relief: The Role of Topical NSAID Patches in Sports Medicine | Yaral Pharma
In this episode, YARAL Pharma CEO, Stephen Beckman joins clinical sports pharmacist Jessica Beal, PharmD. to discuss an important topic for athletes and active individuals – the role topical NSAID patches can play in acute pain management. Listeners can visit www.YARALPharma.com to learn more about the company and its products or connect on LinkedIn. Diclofenac Epolamine Topical System 1.3% Diclofenac Epolamine Topical System 1.3% is a nonsteroidal anti-inflammatory drug (NSAID) used for treating acute pain from minor strains, sprains, and bruises in adults and children aged 6 and older. Serious side effects may include increased risk of cardiovascular and gastrointestinal (GI) events. NSAIDs can raise the risk of heart attack, stroke, gastrointestinal bleeding, ulceration, and perforation of the stomach and intestines, which can be fatal. The risk for serious cardiovascular events may occur early in treatment and may increase with duration of use. Elderly patients and those with a history of peptic ulcer disease or GI bleeding are at higher risk for serious GI events. Do not use in patients who are allergic to diclofenac or any of its ingredients, or have a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Do not use in the setting of coronary artery bypass graft surgery. Avoid use on broken skin. Discontinue immediately if signs of hypersensitivity occur. Patients should be informed about the warning signs and symptoms of liver problems. Discontinue use if abnormal liver tests persist or worsen or if signs of liver disease develop. Avoid using Diclofenac Epolamine Topical System 1.3% in patients with severe heart failure unless the benefits are expected to outweigh the risks. The most common side effects include itching, nausea, and headache. Patients should stop use and consult their doctor at the first sign of skin rash or other signs of sensitivity. Patients should ask their doctor if Diclofenac Epolamine Topical System 1.3% is right for them. For more information and Full Prescribing Information including Boxed Warning and Important Safety Information, visit www.yaralpharma.com Dr. Beal is not affiliated with YARAL Pharma. All views and opinions regarding pain management are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network.
7 total episodes available
Deep-dive analytics for YARAL Pharma
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is YARAL Pharma?
<div class="elementToProof">Welcome to Meet YARAL, a podcast designed to bridge the gap between pharmaceutical companies and the pharmacy profession through candid conversations with pharmacists, healthcare leaders, and YARAL’s executive team.</div> <div class="elementToProof">Each episode highlights the vital role pharmacists play in patient care, unpacks challenges on the front lines, and explores how thoughtful collaboration can lead to better outcomes. Along the way, we share how YARAL’s “Doing Things Differently” approach is helping redefine relationships between industry and practice—from product innovation to patient impact.</div> <div class="elementToProof">YARAL Pharma, launched in 2022, is the U.S. generics subsidiary of IBSA, a longstanding multinational pharmaceutical company headquartered in Lugano, Switzerland. The company is committed to delivering high-quality products across various therapeutic areas, ensuring continuity of supply, and providing affordable authorized and complex generic medicines.</div> <div class="elementToProof">Subscribe to Meet YARAL and be part of the conversation that’s strengthening collaboration between pharmacy and the pharmaceutical industry.</div> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.